Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only FDA label indications (ADHD and BED) are present in the supplied excerpt; most other AI claims (mechanism, CNS stimulant class, formulations, generic availability, and all cost/insurance statements) are not supported or verifiable from the provided label text, and several are not label-specific.
Category Scores
Accurate Statements
Vyvanse (lisdexamfetamine) is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD).
Section 1 INDICATIONS AND USAGE: ADHD in adults and pediatric patients 6 years and older.
Vyvanse (lisdexamfetamine) is a prescription medication used to treat binge eating disorder (BED).
Section 1 INDICATIONS AND USAGE: Moderate to severe binge eating disorder (BED) in adults.
Vyvanse is available in forms including immediate-release and extended-release.
Not supported by the provided excerpt (no dosage forms beyond placeholder text). Marked unsupported because verification is not possible from provided label content.
Unsupported Statements
Vyvanse belongs to the class of central nervous system stimulants.
Provided excerpt does not state a class-of-drugs classification for Vyvanse; it only describes lisdexamfetamine as a CNS stimulant in Section 11 DESCRIPTION but does not explicitly connect this to the 'class of central nervous system stimulants' claim as wording.
Central nervous system stimulants in the class of Vyvanse work by increasing levels of neurotransmitters in the brain such as dopamine and norepinephrine.
Mechanism section provided does not mention dopamine/norepinephrine levels; it states lisdexamfetamine is a prodrug of dextroamphetamine and the exact mode of therapeutic action is not known.
The cost of Vyvanse can vary depending on dosage, form, and manufacturer.
Label excerpt contains no pricing/cost/manufacturer statements.
Generic medications are typically cheaper than brand name medications.
No pricing information in provided label excerpt.
Generic medications are manufactured by multiple companies.
No generic-manufacturing information in provided label excerpt.
Generic medications are subject to less stringent patent laws than brand name medications.
No patent/legal information in provided label excerpt.
There are currently no generic versions of Vyvanse available in the United States.
No information about generic availability in the provided label excerpt.
There are generic versions of lisdexamfetamine approved by the FDA available in other countries.
No information about generic availability/approvals in other countries in provided label excerpt.
Vyvanse (Shire Pharmaceuticals) is the original brand name medication for lisdexamfetamine.
No company origin/brand-history information in provided label excerpt.
Vyvanse ER (Shire Pharmaceuticals) is an extended-release version of Vyvanse designed to release the medication over a longer period of time.
No product-brand extension (ER/XR) definitions or release-duration descriptions in provided label excerpt.
Vyvanse XR (Shire Pharmaceuticals) is an extended-release version of Vyvanse designed to provide a more consistent level of medication in the body.
No XR product-specific release/kinetics statements in provided label excerpt.
The estimated monthly cost for Vyvanse (Shire Pharmaceuticals) is $700-$1,000 for 10 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse (Shire Pharmaceuticals) is $1,200-$1,800 for 30 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse (Shire Pharmaceuticals) is $1,800-$2,500 for 50 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse ER (Shire Pharmaceuticals) is $800-$1,200 for 10 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse ER (Shire Pharmaceuticals) is $1,500-$2,200 for 30 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse ER (Shire Pharmaceuticals) is $2,200-$3,000 for 50 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse XR (Shire Pharmaceuticals) is $900-$1,300 for 10 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse XR (Shire Pharmaceuticals) is $1,800-$2,500 for 30 mg.
No pricing/cost estimates in provided label excerpt.
The estimated monthly cost for Vyvanse XR (Shire Pharmaceuticals) is $2,500-$3,500 for 50 mg.
No pricing/cost estimates in provided label excerpt.
Higher dosages of Vyvanse typically cost more than lower dosages.
No pricing/dosage-cost relationship in provided label excerpt.
The form of Vyvanse (immediate-release or extended-release) can impact the cost.
No pricing/cost information in provided label excerpt.
Different manufacturers may charge different prices for the same medication (Vyvanse).
No pricing information in provided label excerpt.
Insurance coverage can impact the cost of Vyvanse.
No insurance/cost information in provided label excerpt.
Some insurance plans may cover a portion of the cost of Vyvanse.
No insurance coverage information in provided label excerpt.
Some insurance plans may not cover Vyvanse.
No insurance coverage information in provided label excerpt.
Vyvanse can range from $700-$3,500 per month in estimated cost.
No pricing/cost estimates in provided label excerpt.
Vyvanse ER is designed to release medication over a longer period of time.
No ER product-release description in provided label excerpt.
Vyvanse XR is designed to provide a more consistent level of medication in the body.
No XR product-release/consistency description in provided label excerpt.
Contradictions
Important Omissions
For mechanism/class statements, the provided label excerpt includes only that lisdexamfetamine is a prodrug of dextroamphetamine and that the exact mode of therapeutic action in ADHD and BED is not known; the AI did not reflect that 'exact mode... is not known' limitation.
Importance:
Moderate
For the ADHD indication, the label excerpt specifies pediatric patients 6 years and older; the AI claim did not include the age cutoff.
Importance:
Moderate
For BED indication, the label excerpt specifies 'Moderate to severe BED in adults'; the AI claim did not specify severity or adult-only restriction.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most incorrect/unsupported statements concern pricing, generic availability, and broad mechanistic explanations not tied to the provided label excerpt; only indication statements are directly relevant and those are broadly aligned, though missing label qualifiers (age/severity).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Large portion of claims are not supported by the supplied FDA label excerpt (pricing, generic availability, manufacturer/brand history, and detailed ER/XR release descriptions).
Suggested Improvement
Limit claims to what is present in the provided label text (Section 1 indications; Section 11 description of CNS stimulant and prodrug relationship). Remove or re-verify unsupported non-label content, and include label qualifiers for age (≥6 years) and BED (moderate to severe; adults only) when stating indications.